Alzheimer’s Disease Medication: Cognitive Symptoms, Antibodies and Treatment of Agitation

An Alzheimer’s prescription may contain medicines for cognition, treatment of other illnesses and a drug addressing distressing behavior. Each has a different purpose. Supporting cognitive symptoms, slowing average clinical decline in an eligible early disease population and treating agitation are separate objectives. A family needs to understand how each treatment will be evaluated, rather than simply dividing the prescription into old and new drugs.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

When reviewing a prescription, write down what the team is trying to achieve in terms the family can recognize. “Review whether daily cognitive function is being maintained” is more useful than “nourish the brain.” For a behavioral medicine, identify the distress or danger being addressed. Record the start date, prescriber, current formulation, reasons for previous changes and planned review.
The July 2026 U.S. label includes intravenous and subcutaneous initiation arrangements. Monitoring follows the current treatment schedule and applicable formulation. A shorter injection procedure does not remove the need for MRI surveillance. Ask for a written schedule identifying when imaging must occur, who will review it and how an abnormal result affects the next administration.
Fish oil, ginkgo and products sold as brain supplements should not replace assessed treatment on the strength of promotional claims. Correcting an established nutritional deficiency is different from claiming that high-dose supplements reverse Alzheimer’s disease. Tell the clinician about all supplements so that interactions, duplicate ingredients and additional burden can be considered. NCCIH evidence overview

Quick answer

Full guide

This guide reflects information verified through September 2026. International prescribing information helps explain evidence and precautions, but treatment in China depends on the locally authorized indication, formulation and clinical assessment. A medicine appearing in the news does not establish that a particular hospital has stock or that the patient is eligible. NIA treatment information

Give every medicine a clearly stated purpose

When reviewing a prescription, write down what the team is trying to achieve in terms the family can recognize. “Review whether daily cognitive function is being maintained” is more useful than “nourish the brain.” For a behavioral medicine, identify the distress or danger being addressed. Record the start date, prescriber, current formulation, reasons for previous changes and planned review.

A pharmacist can check whether different brand names contain the same ingredient or whether a combination product duplicates another medicine. A patient may genuinely forget having taken a dose. Relying solely on their recollection can therefore lead to accidental repeat administration. A designated caregiver and an actual administration record help the clinical team distinguish a treatment problem from missed doses, interruptions or a recent addition.

The record should follow the patient between clinics and countries. Photographs of packaging are useful, but the team also needs the amount actually taken and the timing of the last dose. If different relatives share responsibility, agree how they will record what has already been given.

Cholinesterase inhibitors primarily address symptoms

Donepezil, rivastigmine and galantamine belong to this group. Choice depends on disease stage, tolerability, other conditions and practical administration. These medicines should not be stacked together casually because they have different names. Their purpose is not immediate restoration of every lost memory or elimination of the disease process. Donepezil information, galantamine information

Report gastrointestinal symptoms, loss of appetite or weight, dizziness and fainting. A history of rhythm problems, gastrointestinal bleeding or significant liver or kidney disease may affect prescribing. The clinician also needs to review other medicines. A single memory score can be influenced by sleep, hearing, mood and the testing situation, so it should not carry the whole decision about whether to continue treatment. NICE medication recommendations

At review, describe daily function and tolerability alongside any formal assessment. A change that seems modest on a test may have a different practical meaning at home. Conversely, a better score does not justify overlooking substantial weight loss or recurrent fainting. The decision should address the balance for this individual.

Formulations require their own instructions

Swallowing ability and the availability of reliable help influence formulation choice. Rivastigmine patches have specific application and replacement instructions. Applying a new patch without removing the previous one can create a medication error. Skin reactions require attention, and delivery through the skin does not eliminate systemic effects. After an interruption, ask the prescriber how treatment should be restarted. Rivastigmine patch information

Ordinary tablets, liquids and modified-release products should not be interchanged by appearance or by a calculation made from the brand name. Some formulations must not be crushed. A pharmacist should inspect the actual pack and demonstrate administration when necessary. The most convenient-looking formulation is useful only if the household can use it correctly.

If the patient resists medication, first explore discomfort, swallowing difficulty, misunderstanding or another cause. Mixing several medicines into food without professional advice can change formulation properties and make the amount swallowed uncertain. A practical discussion with the clinical team is more useful than repeatedly changing the method at home.

Memantine decisions consider stage and kidney function

Memantine has a different mechanism and is commonly considered in the appropriate moderate or severe disease setting. It may be used with a suitable cholinesterase inhibitor when indicated. It is not an oral replacement for an anti-amyloid antibody. Kidney function, dizziness, confusion and constipation are among the matters that may need review. The specific product and adjustment instructions should come from the prescription. Memantine patient information

Progression to a more advanced stage does not automatically mean that every cognitive medicine must be stopped immediately. The clinician should consider previous benefit, treatment burden, swallowing and the goals of care. Longstanding use likewise does not remove the need for periodic reassessment.

Agree on what would trigger a review. Examples include a new difficulty taking the medicine, a suspected adverse effect or a substantial change in function. This makes adjustments easier to interpret than repeated unsupervised stopping and restarting in search of an immediate visible response.

Anti-amyloid antibodies require an eligibility assessment

Lecanemab and donanemab are intended for the relevant early symptomatic Alzheimer’s population with appropriate evidence of amyloid pathology. Assessment also includes MRI findings and factors affecting hemorrhage risk. A routine memory screening result alone does not establish suitability. The treatment objective is slowing average clinical decline in the studied population, not a guarantee that lost abilities will return. Leqembi prescribing information, Kisunla prescribing information

The service needs to include interpretation of safety imaging and a route for managing abnormal findings, in addition to dispensing and administration. Amyloid-related imaging abnormalities, or ARIA, may be asymptomatic but can also be serious. New neurological symptoms need timely assessment, with the drug name and most recent treatment date made available to the treating team.

Do not independently stop an anticoagulant or antiplatelet medicine because of concern about antibody treatment. The relevant clinicians must coordinate decisions about competing risks and the reason the other medicine was prescribed. A medication list is especially important when emergency care occurs away from the memory clinic.

Lecanemab information changed during 2026

The July 2026 U.S. label includes intravenous and subcutaneous initiation arrangements. Monitoring follows the current treatment schedule and applicable formulation. A shorter injection procedure does not remove the need for MRI surveillance. Ask for a written schedule identifying when imaging must occur, who will review it and how an abnormal result affects the next administration.

China’s approval announcement for the subcutaneous initiation formulation appeared in September 2026. Its planned launch does not establish immediate stock at every hospital. Nor should all U.S. initiation and maintenance strengths or schedules be assumed to apply in China. Before arranging travel, the receiving hospital should confirm the locally applicable instructions, available formulation and capacity for continuing treatment. China subcutaneous formulation announcement

The practical question is whether the full care arrangement can be delivered reliably. Obtaining one dose is different from having a prescribing team, monitoring access and a response plan over time. Families comparing services should request those details together.

Agitation needs an assessment before it becomes a prescription question

Pacing, shouting, resisting care or aggression can cause considerable distress. Pain, infection, constipation, urinary retention, sleep disruption, medication effects and environmental triggers may contribute. A sudden change, particularly with altered attention or awareness, requires assessment for an acute cause. Sedation should not become the automatic explanation or response.

Caregivers can record when an episode happened, what preceded it, how long it lasted and what helped. This supports changes to communication, care routines and the environment alongside medical evaluation. If a drug is considered, specify the target behavior and the review plan.

Assess whether distress and danger improve while also watching alertness, walking and eating. A person sleeping through most of the day has not necessarily achieved a good outcome. The intended benefit should be meaningful to the patient as well as manageable for the household.

Brexpiprazole has a defined indication and continuing precautions

The U.S. Rexulti label includes agitation associated with dementia due to Alzheimer’s disease. It is not an as-needed medicine to add whenever the patient becomes upset. The label retains the antipsychotic warning about increased mortality in older people with dementia-related psychosis. Approval for the specified agitation indication cannot be generalized to every behavioral symptom or every dementia diagnosis. Current Rexulti U.S. labeling

The prescriber should discuss symptom severity and risks before starting, then review whether the benefit supports continuing treatment. New marked drowsiness, changes in gait or other problems deserve reassessment. Families should understand the purpose of follow-up rather than assuming that a behavior medicine remains unchanged indefinitely.

A U.S. indication does not establish Chinese authorization for the same use or current local supply. Those questions require separate verification with the treating institution and applicable product documentation.

Auvelity gained a U.S. agitation indication in April 2026

On April 30, 2026, FDA approved extended-release dextromethorphan/bupropion, Auvelity, for agitation associated with dementia due to Alzheimer’s disease in adults. This added a non-antipsychotic option for that U.S. indication. It is not a cure for Alzheimer’s disease, and being outside the antipsychotic class does not make it free of important risks. An over-the-counter cough medicine containing dextromethorphan cannot substitute for the studied combination. FDA approval announcement

Auvelity is not intended as an as-needed treatment. A seizure disorder is a contraindication, and the prescriber must review blood pressure, duplicate ingredients and relevant interactions. The label also addresses risks including hyponatremia and serotonin syndrome. The initiation instructions for agitation must not be copied from a depression prescription, and separate products should not be combined at home to imitate it. These are U.S. regulatory facts, not a promise of availability in China. April 2026 Auvelity label

The addition of another option makes a precise description of the problem more valuable. A clinician needs to distinguish ongoing agitation from a short-lived reaction to pain or acute illness before deciding whether this category of treatment fits the situation.

Sodium oligomannate requires a current status check

Sodium oligomannate, also called GV-971, received conditional approval in China in 2019 for mild to moderate Alzheimer’s disease to improve cognitive function. That historical announcement is not sufficient evidence of current routine supply. Fosun Pharma’s December 2025 regulatory disclosure reported expiry of the original registration in November 2024, suspension of commercial production and subsequent sales, and further confirmatory study and regulatory steps before resuming commercialization. Original approval information, December 2025 disclosure

Payment information also changed. The National Healthcare Security Administration’s 2025 removal list includes sodium oligomannate, with the relevant payment transition ending in June 2026. Its former reimbursement position should not be inserted into a current budget. Official reimbursement removal list

Patients with an existing prescription should bring the package and treatment record for professional review of the product and continuing plan. An old online listing is not a sound basis for stockpiling through an uncertain supplier. Any claim of restored availability should be checked against new, specific documentation.

Include supplements and practical observations in follow-up

Fish oil, ginkgo and products sold as brain supplements should not replace assessed treatment on the strength of promotional claims. Correcting an established nutritional deficiency is different from claiming that high-dose supplements reverse Alzheimer’s disease. Tell the clinician about all supplements so that interactions, duplicate ingredients and additional burden can be considered. NCCIH evidence overview

Bring recent observations about daily life, the administration record and the timing of suspected adverse effects. Focus on one or two difficulties that matter most instead of repeatedly testing the patient every day. A workable medication plan identifies the person responsible for administration, the review date, the contact route for problems and the clinician who will continue care after travel.

The value of the prescription depends partly on whether these arrangements can be maintained. Making them explicit helps the family use an appropriate medicine safely and gives the next clinical team enough context to make a reasoned adjustment.